Tracking genetic changes as low-risk prostate cancer becomes riskier
Part of Cancer, Kidney & urinary clinical trials.
This study looks for genes and biological pathways that may explain why some men’s prostate cancer grows from low risk to higher risk. You may be followed using planned prostate biopsies after an initial low-risk diagnosis managed with active surveillance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have (or previously had) confirmed prostate cancer that is the typical prostate type (adenocarcinoma).
- Your prostate cancer was handled mainly with active surveillance at the National Taiwan University Hospital (NTUH), either in the past or currently.
- You are willing to have a prostate biopsy to check for tumor progression after diagnosis.
- You have not had whole-body cancer treatment for prostate cancer (chemotherapy), radiation to the pelvis, or hormone-blocking treatment (ADT) before the biopsy/operation sample is taken.
- You agree to sign the informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
This study enrolls men with low-risk prostate cancer who are either staying on active surveillance or planning surgery soon. It uses a new “SNEP assay” test to help monitor prostate cancer over time and may improve how doctors track risk.
This study checks whether people with a low chance of prostate cancer can be monitored closely without having an immediate prostate biopsy. It uses PSA blood tests and prostate MRI to sort who may safely wait.
This trial studies how well “active surveillance” works for men with prostate cancer who are considered higher risk because of family history or genetics. It aims to safely monitor the cancer and decide the best timing for treatment if needed, while tracking side effects and follow-up success.
This study follows people with early-stage prostate cancer who choose active surveillance instead of immediate treatment. It aims to see how monitoring with repeat prostate biopsies and follow-up works over time.
Hear when a new Prostate Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.